Protective effect of olmesartan against cardiac ischemia/reperfusion injury in spontaneously hypertensive rats

Lu,Xin; Bi,Yan‑Wen; Chen,Ke‑Biao; Wang,Hong‑Yue

doi:10.3892/etm.2015.2373

Protective effect of olmesartan against cardiac ischemia/reperfusion injury in spontaneously hypertensive rats

Authors:
- Xin Lu
- Yan‑Wen Bi
- Ke‑Biao Chen
- Hong‑Yue Wang
View Affiliations

Affiliations: Department of Cardiovascular Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Cardiovascular Surgery, Taian City Central Hospital, Taian, Shandong 271000, P.R. China
Published online on: March 20, 2015 https://doi.org/10.3892/etm.2015.2373
Pages: 2081-2087
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Olmesartan, as a new angiotensin II receptor blocker, has shown beneficial effects on cardiovascular diseases. Nevertheless, the effect of olmesartan on ischemia/reperfusion (I/R) injury in the hypertensive heart has not been investigated. Therefore, the present study aimed to investigate the effect of olmesartan on I/R injury in spontaneously hypertensive rats (SHRs). Experimental groups were designed with a 2x2 factorial design for olmesartan and I/R effects. In the I/R group, the left anterior descending coronary artery (LAD) was ligated for 40 min followed by a 180‑min reperfusion. In the sham group, SHRs underwent the same surgical procedure as the I/R group, with the exception that the suture passed under the LAD without being tightened. In the Olm‑I/R group, the SHRs received olmesartan (5 mg/kg) for 4 weeks prior to surgery and other procedures were the same as for the I/R group. In the Olm‑sham group, the SHRs received olmesartan (5 mg/kg) for 4 weeks prior to surgery and other procedures were the same as for the sham group. Infarct size was measured for the I/R and Olm‑I/R groups. Blood pressure (BP), serum creatine kinase (CK), left ventricular mass index (LVMI), high mobility group box 1 (HMGB1) protein expression levels and hypoxia‑inducible factor‑1α (HIF‑1α) mRNA expression levels were measured for all four groups. Olmesartan significantly reduced BP and LVMI in the olmesartan‑treated SHRs compared with those in the SHRs that were not treated with olmesartan. HMGB1 and HIF‑1α expression levels were significantly decreased in the Olm‑sham and Olm‑I/R groups compared with those in the sham and I/R groups, respectively. The proportional increase in HIF‑1α expression due to I/R was greater in the olmesartan‑treated rats than in the untreated rats. Serum CK levels were significantly reduced in the Olm‑I/R group compared with those in the I/R group. In conclusion, olmesartan ameliorates left ventricular hypotrophy and protects the heart against I/R injury in addition to lowing BP in SHRs. The protective effect of olmesartan may be partly due to its antioxidative and anti‑inflammatory properties.

View Figures

View References

1	Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJ and Naghavi M: Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: The Global Burden of Disease 2010 study. Circulation. 129:1483–1492. 2014. View Article : Google Scholar : PubMed/NCBI
2	Piper HM, Meuter K and Schäfer C: Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg. 75:(Suppl). S644–S648. 2003. View Article : Google Scholar : PubMed/NCBI
3	Penna C, Mancardi D, Raimonodo S, Geuna S and Pagliaro P: The paradigm of postconditioning to protect the heart. J Cell Mol Med. 12:435–458. 2008. View Article : Google Scholar : PubMed/NCBI
4	Sharma V, Bell RM and Yellon DM: Targeting reperfusion injury in acute myocardial infarction: A review of reperfusion injury pharmacotherapy. Expert Opin Pharmacother. 13:1153–1175. 2012. View Article : Google Scholar : PubMed/NCBI
5	Nogueira-Machado JA and de Oliveira Volpe CM: HMGB-1 as a target for inflammation controlling. Recent Pat Endocr Metab Immune Drug Discov. 6:201–209. 2012. View Article : Google Scholar : PubMed/NCBI
6	Funayama A, Shishido T, Netsu S, et al: Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure. Cardiovasc Res. 99:657–664. 2013. View Article : Google Scholar : PubMed/NCBI
7	Jia Z, Xue R, Liu G, et al: HMGB1 is involved in the protective effect of the PPAR a agonist fenofibrate against cardiac hypertrophy. PPAR Res. 2014:5413942014. View Article : Google Scholar : PubMed/NCBI
8	Andrassy M, Volz HC, Igwe JC, et al: High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation. 117:3216–3226. 2008. View Article : Google Scholar : PubMed/NCBI
9	Zhu H, Li J, Wang S, Liu K, Wang L and Huang L: Hmgb1-TLR4-IL-23-IL-17A axis promote ischemia-reperfusion injury in a cardiac transplantation model. Transplantation. 95:1448–1454. 2013. View Article : Google Scholar : PubMed/NCBI
10	Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. Proc Natl Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
11	Semenza GL: Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol. 76:39–56. 2014. View Article : Google Scholar : PubMed/NCBI
12	Chu W, Wan L, Zhao D, et al: Mild hypoxia-induced cardiomyocyte hypertrophy via up-regulation of HIF-1α-mediated TRPC signaling. J Cell Mol Med. 16:2022–2034. 2012. View Article : Google Scholar : PubMed/NCBI
13	Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–195. 2002. View Article : Google Scholar : PubMed/NCBI
14	Mozaffari MS, Liu JY, Abebe W and Baban B: Mechanisms of load dependency of myocardial ischemia reperfusion injury. Am J Cardiovasc Dis. 3:180–196. 2013.PubMed/NCBI
15	Smith RD, Yokoyama H, Averill DB, Cooke L, Brosnihan KB, Schiffrin EL and Ferrario CM: The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): Rationale and baseline characteristics. Am J Cardiovasc Drugs. 6:335–342. 2006. View Article : Google Scholar : PubMed/NCBI
16	Lorenzen JM, Neunhöffer H, David S, Kielstein JT, Haller H and Fliser D: Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension - results from the EUTOPIA trial. Atherosclerosis. 209:184–188. 2010. View Article : Google Scholar : PubMed/NCBI
17	Hirohata A, Yamamoto K, Miyoshi T, et al: Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: Evaluation by intravascular ultrasound) extension trial. Atherosclerosis. 220:134–138. 2012. View Article : Google Scholar : PubMed/NCBI
18	Swindle JP, Buzinec P, Iorga SR, Ramaswamy K and Panjabi S: Long-term clinical and economic outcomes associated with angiotensin II receptor blocker use in hypertensive patients. Curr Med Res Opin. 27:1719–1731. 2011. View Article : Google Scholar : PubMed/NCBI
19	Hamamoto Y and Koshiyama H: ROADMAP and ORIENTAL Trails: The Re-emergence of J-Curve Ghost? Jpn Clin Med. 2:25–28. 2011.PubMed/NCBI
20	Zhou EH, Gelperin K, Levenson MS, Rose M, Hsueh YH and Graham DJ: Risk of acute myocardial infarction, stroke, or death in patients initiating olmesartan or other angiotensin receptor blockers - a cohort study using the Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 23:340–347. 2014. View Article : Google Scholar : PubMed/NCBI
21	Lim SY, Davidson SM, Hausenloy DJ and Yellon DM: Preconditioning and postconditioning: The essential role of the mitochondrial permeability transition pore. Cardiovasc Res. 75:530–535. 2007. View Article : Google Scholar : PubMed/NCBI
22	Pourkhalili K, Hajizadeh S, Tiraihi T, Akbari Z, Esmailidehaj M, Bigdeli MR and Khoshbaten A: Ischemia and reperfusion-induced arrhythmias: Role of hyperoxic preconditioning. J Cardiovasc Med (Hagerstown). 10:635–642. 2009. View Article : Google Scholar : PubMed/NCBI
23	Zhao H, Wang Y, Wu Y, et al: Hyperlipidemia does not prevent the cardioprotection by postconditioning against myocardial ischemia/reperfusion injury and the involvement of hypoxia inducible factor-1alpha upregulation. Acta Biochim Biophys Sin (Shanghai). 41:745–753. 2009. View Article : Google Scholar : PubMed/NCBI
24	Yoshida A, Suzuki N, Nakano Y, Oho T, Kawada M and Koga T: Development of a 5′fluorogenic nuclease-based real-time PCR assay for quantitative detection of Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. J Clin Microbiol. 41:863–866. 2003. View Article : Google Scholar : PubMed/NCBI
25	Paulis L and Unger T: Novel therapeutic targets for hypertension. Nat Rev Cardiol. 7:431–441. 2010. View Article : Google Scholar : PubMed/NCBI
26	Dai W and Kloner RA: Potential role of renin-angiotensin system blockade for preventing myocardial ischemia/reperfusion injury and remodeling after myocardial infarction. Postgrad Med. 123:49–55. 2011. View Article : Google Scholar : PubMed/NCBI
27	Wassmann S and Nickenig G: Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens Suppl. 24:S15–S21. 2006. View Article : Google Scholar : PubMed/NCBI
28	Chilman-Blair K and Rabasseda X: Olmesartan, an AT1-selective antihypertensive agent. Drugs Today (Barc). 39:745–761. 2003. View Article : Google Scholar : PubMed/NCBI
29	Montecucco F, Pende A, Quercioli A and Mach F: Inflammation in the pathophysiology of essential hypertension. J Nephrol. 24:23–34. 2011. View Article : Google Scholar : PubMed/NCBI
30	Rodríguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S and Vaziri ND: Early and sustained inhibition of nuclear factor-kappaB prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther. 315:51–57. 2005. View Article : Google Scholar : PubMed/NCBI
31	Portaluppi F, Boari B and Manfredini R: Oxidative stress in essential hypertension. Curr Pharm Des. 10:1695–1698. 2004. View Article : Google Scholar : PubMed/NCBI
32	Tang D, Kang R, Xiao W, et al: Nuclear heat shock protein 72 as a negative regulator of oxidative stress (hydrogen peroxide)-induced HMGB1 cytoplasmic translocation and release. J Immunol. 178:7376–7384. 2007. View Article : Google Scholar : PubMed/NCBI
33	Su FF, Shi MQ, Guo WG, Liu XT, Wang HT, Lu ZF and Zheng QS: High-mobility group box 1 induces calcineurin-mediated cell hypertrophy in neonatal rat ventricular myocytes. Mediators Inflamm. 2012:8051492012. View Article : Google Scholar : PubMed/NCBI
34	Krishnan J, Suter M, Windak R, et al: Activation of a HIF1 alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab. 9:512–524. 2009. View Article : Google Scholar : PubMed/NCBI
35	Shyu KG, Liou JY, Wang BW, Fang WJ and Chang H: Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible facor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci. 12:409–420. 2005. View Article : Google Scholar : PubMed/NCBI
36	Kikuchi K, Tancharoen S, Ito T, et al: Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. Int J Mol Sci. 14:18899–18924. 2013. View Article : Google Scholar : PubMed/NCBI
37	Fu M, Zhou J, Xu J, et al: Olmesartan attenuates cardiac hypertrophy and improves cardiac diastolic function in spontaneously hypertensive rats through inhibition of calcineurin pathway. J Cardiovasc Pharmacol. 63:218–226. 2014. View Article : Google Scholar : PubMed/NCBI
38	Opie LH: Reperfusion injury and its pharmacologic modification. Circulation. 80:1049–1062. 1989. View Article : Google Scholar : PubMed/NCBI
39	Zhang X, Wheeler D, Tang Y, et al: Calcium/calmodulin-dependent protein kinase (CaMK) IV mediates nucleocytoplasmic shuttling and release of HMGB1 during lipopolysaccharide stimulation of macrophages. J Immunol. 181:5015–5023. 2008. View Article : Google Scholar : PubMed/NCBI
40	Tang D, Kang R, Zeh HJ III and Lotze MT: High-mobility group box 1, oxidative stress and disease. Antioxid Redox Signal. 14:1315–1335. 2011. View Article : Google Scholar : PubMed/NCBI
41	Dai W, Hale SL, Kay GL, Jyrala AJ and Kloner RA: Cardioprotective effects of angiotensin II type 1 receptor blockade with olmesartan on reperfusion injury in a rat myocardial ischemia-reperfusion injury model. Cardiovasc Ther. 28:30–37. 2010. View Article : Google Scholar : PubMed/NCBI